Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ABP) is a clinical-stage biopharmaceutical company focused on developing next-generation antibody therapeutics, operating in the life sciences and biotechnology sector. The company became a publicly traded entity through a SPAC merger and filed a Form 10-Q with the Securities and Exchange Commission on August 11, 2022 (accession no. 0001193125-22-217578), reporting quarterly financial results as it continued advancing its antibody discovery platform. The filing reflects Abpro's ongoing obligations as a post-combination public company subject to SEC reporting requirements. Sign up at SpacDesk for full filing history, deal metrics, sponsor intelligence, and real-time monitoring on Abpro Holdings and thousands of other SPAC-linked companies.